1. To discuss known population specifics differences in the molecular biology of breast cancer and how this may be clinically relevant.
2. To demonstrate how RNA and transcriptomic data can be leveraged to validate and explore mechanisms of popluation-specific differences.
3. To demonstrate how germline risk and RNA expression data in breast cancer patients can be used to build more broadly applicable prognostication models in breast cancer.
03/16/2020 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Sheila Rajagopal, MD, MPH